Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
MCLA-145 by Merus for Merkel Cell Carcinoma: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Merkel Cell Carcinoma. According to GlobalData, Phase...
MCLA-145 by Merus for Gastric Cancer: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I...
MCLA-145 by Merus for Pancreatic Cancer: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Pancreatic Cancer. According to GlobalData, Phase I...
MCLA-145 by Merus for Cervical Cancer: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Cervical Cancer. According to GlobalData, Phase I...
MCLA-145 by Merus for Colorectal Cancer: Likelihood of Approval
MCLA-145 is under clinical development by Merus and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
Petosemtamab by Merus for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Petosemtamab is under clinical development by Merus and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma....
Petosemtamab by Merus for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Petosemtamab is under clinical development by Merus and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
Petosemtamab by Merus for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Petosemtamab is under clinical development by Merus and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...
Petosemtamab by Merus for Oropharyngeal Cancer: Likelihood of Approval
Petosemtamab is under clinical development by Merus and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
Petosemtamab by Merus for Hypopharyngeal Cancer: Likelihood of Approval
Petosemtamab is under clinical development by Merus and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...
Zenocutuzumab by Merus for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Pre-Registration for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Pre-Registration drugs...
MCLA-129 by Merus for Laryngeal Cancer: Likelihood of Approval
MCLA-129 is under clinical development by Merus and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
Zenocutuzumab by Merus for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive...
Zenocutuzumab by Merus for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Negative...
Zenocutuzumab by Merus for Non-Small Cell Lung Cancer: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Pre-Registration for Non-Small Cell Lung Cancer. According to GlobalData, Pre-Registration...
MCLA-129 by Merus for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
MCLA-129 is under clinical development by Merus and currently in Phase II for Paranasal Sinus And Nasal Cavity Cancer. According...
MCLA-129 by Merus for Oropharyngeal Cancer: Likelihood of Approval
MCLA-129 is under clinical development by Merus and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
Zenocutuzumab by Merus for Metastatic Breast Cancer: Likelihood of Approval
Zenocutuzumab is under clinical development by Merus and currently in Phase II for Metastatic Breast Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of Merus's MCLA-129?
MCLA-129 is a monoclonal antibody commercialized by Merus, with a leading Phase II program in Esophageal Squamous Cell Carcinoma (ESCC)....
Risk adjusted net present value: What is the current valuation of Merus's Petosemtamab?
Petosemtamab is a monoclonal antibody commercialized by Merus, with a leading Phase II program in Esophageal Squamous Cell Carcinoma (ESCC)....